Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

About this update from Agenus Inc.

[{"type":"text","content":" LEXINGTON, Mass.--(BUSINESS WIRE)--\nAgenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab (BOT) in combination with balstilimab (BAL) in patients with relapsed/refractory (R/R) metastatic sarcomas.\n\n\nThese findings further reinforce the consistency of the BOT/BAL combination, which has already shown activity and a favorable safety profile across both multiple “warm and cold” tumor types, including colon cancer, lung cancer, melanoma and ovarian cancers.\n\n\nPatients with advanced sarcomas face poor outcomes and have limited treatment options, underscoring the urgent need for innovative therapies. This Phase 1 study evaluated the safety and efficacy of botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in this challenging patient population.\n\n\n“The publication in the Journal of Clinical Oncology further underscores the significant potential of botensilimab and balstilimab to address ‘cold’ tumors like certain subtypes of refractory sarcomas,” said Dr. Breelyn A. Wilky, University of Colorado Cancer Center. “These findings highlight the ability of this combination to deliver meaningful clinical benefits, including durable responses and extended survival, for patients who previously had very limited treatment options.”\n\n\nPublication Highlights\n\n\nStudy Overview\n\n\n\nThis open-label multicenter trial (NCT03860272) enrolled patients across multiple sarcoma subtypes, including angiosarcoma and leiomyosarcoma—tumor types historically resistant to traditional checkpoint inhibitors. Patients were heavily pretreated with a median of three prior lines of therapy and 15% received previous PD(L)-1 therapy.\n\n\n\nIn this expansion cohort, BOT was administered intravenously at 1 mg/kg or 2 mg/kg every 6 weeks in combination with BAL at 3 mg/kg every 2 weeks for up to 2 years.\n\n\nAll patients were evaluable for safety and 52 patients for efficacy.\n\n\n\n\n\n\nEfficacy Highlights\n\n\n\nDurable responses were observed across immunologically \"cold\" soft tissue sarcoma types, including visceral angiosarcoma and leiomyosarcoma.\n\n\n\nOverall response rate (ORR) was 19.2% for the overall study population (n=52). Among angiosarcoma patients (n=18), ...

More updates from Agenus Inc.